Skip to Main Content

KMAP BULLETIN: Pharmaceutical Prior Authorization Updates – August 2026

Date: 09/15/26

KMAP GENERAL BULLETIN 26159 (PDF)

Effective with dates of service on or after October 19, 2026, the following medications require Clinical Prior Authorization (PA):

  • Atomoxetine (Atoncy™) – Oral Solution
  • Bevacizumab-nwgd (Jobevne™) – Vial
  • Brensocatib (Brinsupri®) – Tablet
  • Carboplatin (Kyxata®) – Vial
  • Cephalexin 500 mg – Tablet
  • Cephalexin 750 mg – Capsule
  • Denosumab-desu (Jubereq®) – Vial
  • Denosumab-desu (Osvyrti®) – Prefilled Syringe
  • Elivaldogene autotemcel (Skysona®) – Cell Suspension
  • Filgrastim-laha (Filkri™) – Prefilled Syringe
  • Fluorouracil (Favlyxa™) – Vial
  • Gemcitabine (Avgemsi™) – Vial
  • Icotrokinra (Icotyde™) – Tablet
  • Isatuximab-irfc (Sarclisa Escena ™) – Vial
  • Lidocaine (Ztlido®) – Patch
  • Linvoseltamab-gcpt (Lynozyfic®) – Vial
  • Milsaperidone (Byzant™) – Tablet
  • Natalizumab-sztn (Tyruko®) – Vial
  • Nerandomilast (Jascayd®) – Tablet
  • Nilotinib (Cavhanza™) – Tablet
  • Orforglipron (Foundayo™) – Tablet
  • Pegvaliase-pqpz (Palynziq®) – Prefilled Syringe
  • Pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) – Vial
  • Pemetrexed disodium (Pemrydi RTU®) – Vial
  • Remibrutinib (Rhapsido®) – Tablet
  • Ropeginterferon alfa-2b (BESREMi®) – Prefilled Syringe, Prefilled Pen
  • Ruxolitinib (Jakafi XR®) – Extended-release Tablets
  • Semaglutide (Wegovy® HD) – Injection
  • Sepiapterin (Sephience®) – Oral Powder
  • Telisotuzumab vedotin (Emrelis ™) – Vial
  • Tocilizumab-anoh (Avtozma®) – Prefilled Syringe, Autoinjector, Vial
  • Ustekinumab-hmny (Starjemza®) – Prefilled Syringe, Vial
  • Vepdegestrant (Veppanu®) – Tablet

Grandfather PA Process

A Grandfather PA process is in place for KanCare patients according to the following guidelines:

  • For members currently taking a maintenance drug that newly requires a PA, and the member has been 80% adherent, the member will receive a Grandfather PA.
  • For members who have filled a maintenance drug that newly requires a PA, and the member has filled the medication once or with an adherence rate of less than 80%, the member will not be given a Grandfather PA.
  • For members currently taking medications considered nonmaintenance (acute or seasonal treatments) (For example, acne agents, muscle relaxants, NSAIDs, antihistamines, etc.), no Grandfather PA will be given.


Reference the Prior Authorization – Clinical Criteria page on the Kansas Department of Health and Environment (KDHE) website for Clinical PA information.

Note: The effective date of the policy is October 19, 2026. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.